Ind-Swift Laboratories cash flow

Latest FY26

Cash from operations: −₹63.2cr−₹25.5 cr in FY25
Capital spending: ₹87.7cr+36.2% on FY25
Free cash flow: −₹151cr−₹89.9 cr in FY25
Cash from financing: ₹142cr+104.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	30.6	24.5	53.3	58.4
	—	−1.4	0.0	0.0	0.0
	—	0.0	0.0	45.1	83.5
	—	−4.8	0.0	−2.5	−3.1
	—	22.0	−223	−0.0	26.6
	—	−55.3	0.0	−387	0.0
	—	−33.8	−43.2	32.9	−10.1
	—	−40.3	96.8	−130	−36.7
	—	−76.0	−6.4	−437	−21.6
	—	46.7	−28.7	0.0	0.0
	—	0.0	0.0	6.9	−14.7
	—	0.0	−67.0	26.0	31.8
	—	0.0	3.5	0.0	0.0
	—	0.0	0.0	24.8	0.0
Cash from operating activities
	104	49.0	258	582	86.5
	—	−112	−244	−767	114
	—	−63.2	14.1	−185	201
	—	0.0	−75.3	−18.4	−5.9
	—	0.0	−39.2	0.0	0.0
	—	0.0	0.0	22.5	0.0
	—	0.0	3.3	0.1	0.2
	—	−63.2	−25.5	−181	195
Cash from investing activities
	—	87.7	64.4	44.5	12.8
	—	1.2	38.6	2.9	0.1
	—	41.6	0.0	0.0	0.0
	—	0.0	−126	0.0	0.0
	—	0.0	0.0	81.1	1.3
	—	55.5	42.0	18.4	0.5
	—	−72.7	−110	−104	−13.4
Cash from financing activities
	—	163	0.0	0.0	0.0
	—	0.0	92.6	0.0	0.0
	—	0.0	27.6	0.0	0.0
	—	15.1	6.6	37.4	45.9
	—	0.0	−0.7	0.0	0.0
	—	5.5	41.9	126	129
	—	0.0	3.2	72.8	11.2
	—	−0.6	0.0	935	0.0
	—	142	69.2	699	−186
	—	5.9	−65.9	414	−4.4
	—	5.5	−0.6	−0.4	0.0
	—	11.4	−66.5	413	−4.4
	—	—	—	431	−4.4
Reference items
	104	45.1	−19.4	254	229
	13.8%	7.0%	−3.5%	19.9%	19.0%
	−151	−151	−89.9	−225	182
	—	−179	−108	−1,196	—
	−₹17.38	−₹17.38	−₹10.35	−₹25.96	₹20.94
	—	−1.53×	−0.10×	−0.43×	4.09×
	—	0.0	3.3	0.1	0.2
	—	5.5	41.9	126	129

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

INDSWFTLAB₹409.80

Ind-Swift Laboratories Limited

· Pharma & Health

₹ CrorePeersSMSPHARMA SOLARA DCAL HIKAL UNICHEMLAB GUFICBIO PANACEABIO RPGLIFEMcap ₹3,559 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	58.4	53.3	24.5	30.6	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.0	-1.4	—
+ Finance Costs	83.5	45.1	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	-3.1	-2.5	0.0	-4.8	—
+ Other Non-cash Items	26.6	-0.0	-223.2	22.0	—
+ Other — Cash Effects are Investing / Financing	0.0	-386.6	0.0	-55.3	—
Changes in Working Capital
+ Inventories	-10.1	32.9	-43.2	-33.8	—
+ Trade Receivables — Current	-36.7	-130.0	96.8	-40.3	—
+ Other Current Assets	-21.6	-436.5	-6.4	-76.0	—
+ Other Non-current Assets	0.0	0.0	-28.7	46.7	—
+ Other Financial Liabilities — Current	-14.7	6.9	0.0	0.0	—
+ Other Current Liabilities	31.8	26.0	-67.0	0.0	—
+ Provisions — Current	0.0	0.0	3.5	0.0	—
+ Provisions — Non-current	0.0	24.8	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	86.5	581.8	257.8	49.0	104.3
+ Total Adjustments (incl. Working Capital)	114.2	-766.7	-243.7	-112.2	—
Cash from Operations (pre-tax)	200.7	-185.0	14.1	-63.2	—
+ Interest Received — Operating	-5.9	-18.4	-75.3	0.0	—
+ Interest Paid — Operating	0.0	0.0	-39.2	0.0	—
+ Other Inflows / (Outflows) — Operating	0.0	22.5	0.0	0.0	—
+ Income Taxes Paid	0.2	0.1	3.3	0.0	—
Cash from Operating Activities	194.6	-180.9	-25.5	-63.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	12.8	44.5	64.4	87.7	—
+ Disp of Fixed Assets	0.1	2.9	38.6	1.2	—
+ Acq of Investment Property	0.0	0.0	0.0	41.6	—
+ Disp of Investment Property	0.0	0.0	-125.8	0.0	—
+ Acq of Subsidiaries / Businesses (net)	1.3	81.1	0.0	0.0	—
+ Interest Received — Investing	0.5	18.4	42.0	55.5	—
Cash from Investing Activities	-13.4	-104.3	-109.6	-72.7	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	163.0	—
+ Proceeds from Other Equity Instruments	0.0	0.0	92.6	0.0	—
+ Proceeds from Borrowings	0.0	0.0	27.6	0.0	—
+ Repayment of Borrowings	45.9	37.4	6.6	15.1	—
+ Payment of Lease Liabilities	0.0	0.0	-0.7	0.0	—
+ Interest Paid	128.5	126.0	41.9	5.5	—
+ Income Taxes (Paid) / Refund — Financing	11.2	72.8	3.2	0.0	—
+ Other Inflows / (Outflows) — Financing	0.0	935.2	0.0	-0.6	—
Cash from Financing Activities	-185.7	698.9	69.2	141.8	—
Net Changes in Cash (pre-FX)	-4.4	413.7	-65.9	5.9	—
+ Effect of FX Rate Changes on Cash	0.0	-0.4	-0.6	5.5	—
Net Changes in Cash	-4.4	413.3	-66.5	11.4	—
Closing Cash	-4.4	431.5	—	—	—
Reference Items
EBITDA	229.2	254.2	-19.4	45.1	103.6
EBITDA Margin %	18.98	19.85	-3.45	7.03	13.77
Free Cash Flow (CFO − Capex)	181.8	-225.4	-89.9	-150.9	-150.9
Free Cash Flow to Equity	—	-1,196.4	-107.8	-179.1	—
Free Cash Flow per Basic Share	20.94	-25.96	-10.35	-17.38	-17.38
Cash Flow to Net Income	4.09	-0.43	-0.10	-1.53	—
Cash Paid for Taxes	0.2	0.1	3.3	0.0	—
Cash Paid for Interest	128.5	126.0	41.9	5.5	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.